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Objective. In this work we studied the correlation between platelet count, platelet activation, and systemic inﬂammation in over-
weight, obese, and morbidly obese individuals. Methods and subjects. A total of 6319 individuals participated in the study. Com-
plete blood counts, high sensitivity C-reactive protein (hs-CRP) serum levels, and body mass index (BMI) were measured during
routine checkups. Platelet activation markers were studied among 30 obese (BMI = 41 ± 8kg/m 2) and 35 nonobese (BMI =
24 ± 3kg/m 2) individuals. Platelet activation status was evaluated by ﬂow cytometry using speciﬁc antibodies against the acti-
vated platelet membrane glycoprotein IIb/IIIa, p-selectin (CD-62 p), and binding of Annexin-V to platelet anionic phospholipids.
Results. Overweight, obese, and morbidly obese females had signiﬁcantly elevated platelet counts (P<. 0001) compared with
normal-weight females. No signiﬁcant elevation of platelet counts was observed in the male subgroups. A signiﬁcant age adjusted
correlation between BMI and platelet counts (P<. 0001) was found among females. This correlation was attenuated (P = .001) af-
ter adjustment for hs-CRP concentrations. The ﬂow cytometry analysis of platelets showed no signiﬁcant diﬀerences in activation
marker expression between nonobese and obese individuals. Discussion. Obesity may be associated with elevated platelet counts in
females with chronic inﬂammation. Obesity is not associated with increased platelet activation.
Copyright © 2008 Dorit Samocha-Bonet et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Obesity, a major risk factor for cardiovascular disease, is
associated with an accelerated atherothrombotic process,
resulting in increased morbidity and mortality [1]. Cy-
tokines, such as Interleukin-6 (IL-6), originating from adi-
pose tissue, have a fundamental role in the pathogenesis of
atherothrombosis [2]. IL-6 acts synergistically with other in-
terleukins,growthfactors,andthrombopoietininmegakary-
ocytopoiesis; in-vivo administration of IL-6 to both mon-
keys and humans reportedly increased circulating platelet
counts [3]. Higher platelet counts are associated with ad-
verse clinical outcome in patients with ST-elevation myocar-
dialinfarction[4].Theassociationbetweenincreasedplatelet
counts and platelet activation is unclear; in patients with
carotid stenosis, increased platelet counts, and leukocyte-
platelet complex formation, that is, platelet activation, was
associated with the risk of stroke [5]; platelet count and
platelet activation are associated in patients with chronic in-
ﬂammation, such as patients with essential thrombocytosis
[6],and patients withinﬂammatory bowel diseases [7]. Obe-
sity is a chronic inﬂammation state [2], yet the association
between platelet count and platelet activation has never been
studied in obese subjects, to the best of our knowledge.
There is an ongoing debate on whether obesity is accom-
panied by platelet activation. The ﬁndings that the leptin re-
ceptor is expressed in platelets [8] and that leptin potenti-
ates platelet aggregation by agonists [8, 9] shed light on a
possible direct link between obesity and thrombotic compli-
cation. Davi et al. demonstrated platelet activation in obese2 Mediators of Inﬂammation
individuals by measuring urine excretion of a thrombox-
ane B2 (TxB2) metabolite (11-dehydrothromboxane B2, 11-
dehydro TxB2)[ 10]. In contrast, other studies found no ev-
idence of increased platelet activation in obese individuals
[11], in obese and overweight women [12], in overweight
prediabetics [13], and further reported a negative correla-
tion between plasma β-thromboglobulin (BTG), a marker of
platelet release, and body weight [14]. In the present study,
westudiedplateletcountandplateletactivationinobesesub-
jects.
2. MATERIALS AND METHODS
2.1. Patients
Participants were all part of the Tel-Aviv Medical Center
Inﬂammation Survey (TAMCIS). The TAMCIS is a cross-
sectional study performed on a group of apparently healthy
individuals, consisting of employees of the Tel-Aviv Sourasky
Medical Center (TASMC) and the Tel-Aviv Municipality.
The study was conducted between September 2002 and July
2006. All patients gave their informed consent to partici-
pate in the survey in writing, according to the local ethics
committee instructions. Recruitment for the study was per-
formed through announcements in the monthly salary slips
of the Tel-Aviv Medical Center personnel. Platelet count
was studied initially in 9115 subjects. Excluded were indi-
viduals with an underlying chronic inﬂammatory disease
(n = 1677), such as arthritis, inﬂammatory bowel disease,
individuals with an acute or recent inﬂammatory condi-
tion, and individuals with a history of myocardial infarc-
tion or surgery during the past six months. Also excluded
were individuals treated with antiplatelets, anticoagulants,
hormone replacement therapy, oral contraception, systemic
steroids, immunosuppressive agents, and nonsteroidal anti-
inﬂammatory drugs (n = 1119). Medical conditions were
self-reported, but were conﬁrmed by a physician who took
historyandexaminedeachindividual.Plateletactivationwas
studied in 65 randomly assigned patients: 30 obese subjects
from the obesity clinic and 35 nonobese subjects from the
general study. In this group, subjects taking antiplatelets,
hormone replacement therapy, and oral contraception were
not excluded.
2.2. Cardiovascularriskfactors
The diagnosis of diabetes mellitus was consistent with the
guidelines of the American Diabetic Association. Diabetic
individuals were those with fasting plasma glucose level of
126mg/dLorhigher,orthosewhoweretakinghypoglycemic
agents [15]. The diagnosis of essential hypertension was con-
sistent with the seventh report of the Joint National Com-
mittee on prevention, detection, evaluation, and treatment
of high blood pressure (JNC 7). Hypertensive individuals
were those with systolic blood pressure (BP) of 140mmHg
orhigherand/oradiastolicBPof90mmHgorhigherrepeat-
edly, or individuals who were taking antihypertensive agents
[16].
2.3. Metabolicsyndromedeﬁnition
Metabolic syndrome was deﬁned as having at least three
of the following: men with high-density lipoprotein (HDL)
cholesterol ≤ 40mg/dL, women with HDL cholesterol ≤
50mg/dL, triglyceride ≥ 150mg/dL for both genders, blood
pressure ≥ 130/85mmHg for both genders, fasting plasma
glucose (FBG) ≥ 110mg/dL for both genders, and waist
circumference ≥ 102cm for men and ≥88cm for women
[15]. Fasting glucose levels and lipid proﬁles were measured
by routine biochemical determinations. Blood samples for
plasma glucose levels and lipid proﬁle were drawn after an
overnight fast from all individuals.
2.4. Plateletcountsandinﬂammatorymarkers
Complete blood counts were performed using the Coulter
STKS (Beckman Coulter, Nyon, Switzerland) automatic cell
analyzer. High-sensitivity C-reactive protein (hs-CRP) was
measured using the Boering BN II nephelometer (DADE
Boering, Marburg, Germany) according to Rifai et al. [17].
Blood samples for complete blood counts and systemic in-
ﬂammation markers were drawn after an overnight fast from
all individuals.
2.5. Plateletactivationmarkers
Platelet activation was studied as previously described [18,
19]. Brieﬂy, blood was collected in citrate-containing sy-
ringes (1:10 volume of 3.8% citrate) and processed imme-
diately to prevent possible in-vitro activation of platelets.
Platelet-rich plasma was prepared immediately by standard
slow centrifugation (150×g for 12 minutes) and used for
ﬂow cytometry analysis of platelet activation markers. A 5μL
platelet suspension (250 × 109 platelets/L) was immediately
incubated with Ca++-a n dM g ++-free phosphate-buﬀered
saline (PBS) and monoclonal antibodies (MoAb) in saturat-
ing concentrations, in a total volume of 50μL. An HBSS-
HEPES buﬀer containing 2.5mM CaCl2 was used for the
incubation with Annexin-V. Following 30 minutes incuba-
tion at 4◦C, the samples were diluted 1:10 with the same
buﬀe ra n da n a l y z e db yaF A C S C a l i b u rﬂ o wc y t o m e t e r( B e c -
ton Dickinson Biosciences, Calif, USA). The samples were
not lysed or ﬁxed and were analyzed immediately. MoAbs
included phycoerythrin (PE)-labeled CD41 against resting
and activated glycoprotein IIb/IIIa (Immunotech, Marseille,
France), ﬂuorescein-isothiocyanate (FITC)-labeled PAC-1
against the activated conformation of glycoprotein IIb/IIIa
(BectonDickinsonBiosciences,CA),FITC-labeledP-selectin
(CD62p), an α-granule membrane glycoprotein expressed
on the platelet surface during secretion (Immunotech, Mar-
seille, France), and FITC-labeled annexin-V, which is known
to react with platelet anionic-phospholipids, such as phos-
phatydilserine (PS) exposed on platelets following activa-
tion (R&D Systems, Minneapolis, MN). Isotype-matched
MoAbs (Immunotech, France; DAKO, DK) were used as
negative controls, and platelets treated in-vitro with adeno-
sine diphosphate (ADP) and Ca++-Ionophore A23817 (ﬁ-
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as positive controls. Platelets were identiﬁed by light-scatter
properties and CD41 expression and analyzed for binding
of the speciﬁc Ab. All measurements were performed on list
mode using logarithmic scales and 10,000 platelets were an-
alyzed in each sample using the Cellquest Pro software (Bec-
ton Dickinson). The results are expressed as mean ﬂuores-
cence intensity (MFI) units for the studied markers of acti-
vation.
2.6. Statisticalanalysis
For platelet count analysis, subjects were divided into four
groups based on their BMI: normal weight (BMI < 25), over-
weight (25 < BMI < 29.9), obese (30 < BMI < 39.9), and
morbidly obese (BMI ≥ 40). Data was analyzed separately
for males and females due to gender diﬀerences in baseline
inﬂammatory proﬁles and platelet counts [20]. Diﬀerences
in prevalence of cardiovascular risk factors and cardiovascu-
lardiseasebetweenthevariousBMIsubgroupswereanalyzed
usingthechi-squaretestfordiscretevariables,andanalysisof
variance (ANOVA) with the general linear model for contin-
uous variables. Since hs-CRP had a non-normal distribution
to begin with, a logarithmic transformation of hs-CRP was
used for all statistical procedures. Diﬀerences between the
BMI subgroups in terms of platelet counts, hemoglobin lev-
els, and hs-CRP levels were analyzed using ANOVA. Platelet
counts, hemoglobin levels and hs-CRP levels for overweight,
obese, and morbidly obese subgroups were compared with
thoseofthenormal-weightsubgroupusingthegenerallinear
model with post hoc multiple comparisons by the method
of Scheﬀe. The student’s t test was used to evaluate diﬀer-
ences in platelet counts between subjects with or without the
metabolic syndrome. ANOVA was used to evaluate the as-
sociation between BMI and platelet counts after age- and hs-
CRP-adjustments.Forplateletactivationanalysis,65subjects
were divided into two groups based on their BMI: nonobese
(BMI < 30) and obese (BMI ≥ 30). The student’s t test and
Mann-Whitney test were used to evaluate diﬀerences in the
studied markers between the two groups. BMI and waist-to-
hipratiowerenormallydistributedinbothgroups.TheSPSS
statistical package was used (SSPS Inc., Chicago, IL, USA).
3. RESULTS
3.1. PlateletcountsandBMIstatus
Platelet counts were studied among 6319 individuals, 4352
males and 1967 females. The mean age of the cohort was
44.6 ± 10.4 years. Overall, 1234 (19.5%) subjects had hy-
pertension, 246 (3.9) subjects had diabetes mellitus, 1923
(30.4%) had dyslipidemia, 85 (1.3%) had history of ischemic
heart disease, and 9 (0.1%) had history of ceberovascular
accident. Overall, 2463 (39.0%) were normal weight, 2749
(43.5%) were overweight, 1058 (17%) were obese, and 49
(0.8%) were morbidly obese. The prevalence of hyperten-
sion, diabetes mellitus, and history of myocardial infarction
signiﬁcantly increased with BMI category (Table 1).
Platelet counts increased with BMI in both genders.
However, only among females, the platelet counts were sig-
niﬁcantly elevated in the overweight (P = .015), obese (P
< .0001), and morbidly obese (P < .0001) subgroups com-
pared with the normal-weight subgroup after adjustment for
age, diabetes mellitus, and hypertension. Using ANCOVA,
platelet counts were still associated with BMI among females
after adjustment for age and hs-CRP (P = .034). Platelet
counts were elevated, though not statistically signiﬁcant, in
the overweight, obese, and morbidly obese male subgroups
compared with the normal-weight subgroup. The associa-
tion between obesity and inﬂammation was apparent by an
increment in hs-CRP concentrations with BMI categories in
both males and females (Table 2). Mean platelet counts were
signiﬁcantly higher in obese females with the metabolic syn-
drome compared with obese females without the metabolic
syndrome (P = .032). In the overweight and morbidly obese
female subgroups, the platelet counts tended to be higher
in women with the metabolic syndrome, however, this ten-
dency did not reach statistic signiﬁcance (Table 3). Finally,
there was a signiﬁcant age-adjusted correlation between BMI
and platelet counts (P < .0001) in females. This correlation
was attenuated but remained signiﬁcant (P = .001) after ad-
justment for hs-CRP concentrations.
3.2. PlateletactivationandBMIstatus
Platelet activation was studied in 65 individuals, 49 females,
and 16 males. They were divided according to their BMI lev-
els into nonobese (BMI < 30, n = 35) and obese (BMI ≥ 30,
n = 30) subjects. Their clinical characteristics and laboratory
ﬁndings are summarized in Table 4. Nine of the obese sub-
jects were on antihypertensive drugs and 3 were on low-dose
aspirin therapy. In the nonobese subgroup, 7 subjects were
on estrogen treatment (oral contraceptives or hormone re-
placement therapy), and 4 were on low-dose aspirin ther-
apy. The obese group diﬀered from the nonobese group
in fat distribution, as evidenced by larger waist circumfer-
ences and larger waist-to-hip ratios. Signiﬁcant diﬀerences
between obese and nonobese individuals were also found
in the metabolic markers FBG, HDL-cholesterol and serum
triglyceride concentrations. Table 4 displays the platelet ac-
tivation status as measured by the expression of the MoAb
studied. No signiﬁcant diﬀerences were found in platelet ac-
tivation status between the groups. Additionally, no statisti-
callysigniﬁcantcorrelationwasfoundbetweenBMIorwaist-
to-hip ratios and indices of platelet activation (Table 5).
4. DISCUSSION
It has been well established that obesity is associated with
low-grade subclinical and smoldering inﬂammation [2, 21,
22]. Both BMI and body fat mass have been shown to cor-
relate with total leukocyte counts [23]. The Atherosclero-
sis Risk in Community (ARIC) study demonstrated a posi-
tive correlation between leukocyte and platelet counts [24],
but no signiﬁcant correlation between obesity and platelet
counts.Moreover,ithasnotyetbeenestablishedwhetherele-
vated platelet counts in obese individuals are associated with
platelet activation. The answer to this question is especially4 Mediators of Inﬂammation
Table 1: Clinical characteristics of subjects for platelet count analysis stratiﬁed by BMI.
BMI <25 25–29.9 30–39.9 >40 P-value
n 2460 2749 1057 49 —
Age (mean ± SD) 41.8 ±10.6yrs 45.9 ±10.1yrs 47.7 ±9.0yrs 45.6 ±7.6yrs <.0001
Hypertension 246 (10.0%) 596 (21.7%) 370 (35%) 22 (44.9%) <.0001
Diabetes mellitus 38 (1.5%) 91 (3.3%) 106 (10.0%) 11 (22.4%) <.0001
Dyslipidemia 451 (18.3%) 911 (33.1%) 451 (51.1%) 20 (40.8%) <.0001
Ischemic heart disease 30 (1.2%) 35 (1.3%) 19 (1.8%) 1 (2.0%) .53
Past CVA 4 (0.2%) 1 (0.0%) 3 (0.3%) 1 (0.02%) .001
BMI = body mass index; MI = myocardial infarction; CVA = cerebrovascular accident.
Table 2: Age, hypertension, and diabetes mellitus adjusted estimated marginal mean (standard error of the mean) of platelets count,
hemoglobin concentration, and CRP stratiﬁed by BMI.
Body mass index <25 25–29.9 30–39.9 >40 P-value
Females
N 1015 585 341 26 —
Platelet count (×109/L) 260 (4) 270 (4)∗ 281 (4)∗ 307 (11)∗ <.0001
Hemoglobin (g/L) 13.2 (0.08) 13.2 (0.08) 13.2 (0.08) 13.2 (0.21) .893
hs-CRP 1.2 (1.1) 2.5 (1.1)∗ 5.2 (1.1)∗ 9.3 (1.2)∗ <.0001
Males
N 1448 2164 717 23 —
Platelet count (×109/L) 241 (3) 242 (2) 246 (3) 260 (11) .11
Hemoglobin (g/L) 14.8 (0.04) 15.0 (0.04)∗ 15.0 (0.05)∗ 14.8 (0.20) <.0001
hs-CRP 1.1 (1.0) 1.7 (1.0)∗ 2.6 (1.0)∗ 6.2 (1.2)∗ <.0001
∗P < .05 compared with the BMI <25 group.
Table 3: Platelet counts in overweight, obese, and morbidly obese females with and without the metabolic syndrome.
Metabolic syndrome No metabolic syndrome P-value
BMI 25–29.9 (n = 585) 270 ± 67 (n = 73) 260 ± 56 (n = 512) .23
BMI 30–39.9 (n = 341) 283 ± 62 (n = 119) 268 ± 60 (n = 222) .032
BMI > 40 (n = 26) 314 ± 53 (n = 14) 292 ± 52 (n = 12) .29
BMI = body mass index.
Table 4: Clinical data, laboratory ﬁndings, and platelet activation markers for subjects in the platelet activation analysis.
Nonobese Obese P-value
n 35 30 —
Age (years) 43 ± 12 41 ± 13 .2
Body mass index (kg/m2)2 4 ± 2.7 41 ± 7.7 <.0001
Waist circumference (cm) 83 ± 12 120 ± 14 <.0001
Hip circumference (cm) 96 ± 6 131 ± 19 <.0001
Waist/hip ratio 0.86 ± 0.13 0.93 ± 0.15 .06
Blood glucose (mg/dl) 82 ± 8 105 ± 26 .003
HDL cholesterol (mg/dl) 62 ±17 46 ± 12 <.0001
Triglyceride levels (mg/dl) 119 ± 63 170 ± 87 .01
Total cholesterol (mg/dl) 232 ± 49 216 ± 47 .2
LDL cholesterol (mg/dl) 148 ± 47 136 ± 41 .3
Platelet count (×109/L) 259 ± 55 263 ± 55 .7
Platelet activation markers (MFI, range given in parentheses)
PAC-1 binding 8.4 ±5.9 (1.8–24.6) 6.5 ±4.7 (1.7–22.7) .09
P-selectin (CD-62p) 2.1 ±0.8 (1.3–4.4) 2.2 ±0.6 (1.5–3.6) .3
Annexin-V binding 4.4 ±2.3 (2.1–12.2) 4.7 ±1.5 (2.4–8.0) .15
HDL = high-density lipoprotein; LDL = low-density lipoprotein; MFI = mean ﬂuorescence intensity.Dorit Samocha-Bonet et al. 5
Table 5: Correlations between platelet activation markers, body
mass index, and waist-to-hip ratios for subjects in the platelet ac-
tivation analysis.
Platelet activation markers BMI (kg/m2) Waist-to-hip ratio
n 65 65
PAC-1 binding r = −0.2 r = 0.004
P = .1 P = .9
CD62p expression r = −0.05 r = −0.12
P = .7 P = .4
Annexin-V binding r = 0.06 r = −0.15
P = .6 P = .3
BMI = body mass index; MFI = mean ﬂuorescence intensity.
relevant when primary prevention by antiplatelet therapy is
considered for individuals at risk.
The results of the present study demonstrate an associ-
ation between obesity and platelet counts in females prob-
ably due to higher body fat mass. Yudkin et al. [21]h a v e
demonstratedanassociationbetweenobesityandIL-6levels.
A large proportion of IL-6 in the circulation originates from
the adipose tissue that in turn may contribute to atherogene-
sis and thrombosis, by promoting inﬂammation. One of the
proposed mechanisms for IL-6 contribution to atherogenesis
and thrombosis is its eﬀect on platelets, ﬁbrinogen concen-
trations,andcoagulation[2].IL-6,inadditiontootherinter-
leukins, plays a crucial role in the proliferation of megakary-
ocyte progenitors and acts synergistically with thrombopoi-
etinandstemcellfactorinstimulatingmegakaryocytopoiesis
[3, 25, 26]. Thus it is conceivable that the elevated platelet
counts found in obese females in the present study are sec-
ondary to the presence of a chronic inﬂammation as evident
by elevated hs-CRP levels. In fact, the correlation between
BMI and platelet counts found in females was attenuated
once adjusted for hs-CRP levels.
The ambiguity found in the literature regarding the role
of platelet activation in obese individuals stems from em-
ployment of diﬀerent markers to evaluate platelet activa-
tion in previous studies. Tangorra et al. [27]a n dM e a d e
et al. [28] used aggregating agents to test platelet suscep-
tibility to aggregation. Both groups showed no correlation
between obesity and the susceptibility of platelets to aggre-
gating agents. Davi et al. and Licata et al. used 11-dehydro-
TxB2 excreted in urine to evaluate platelet activation. In an
earlier (relatively small) study, they found no diﬀerences in
11-dehydro-TxB2 excretion between obese and nonobese in-
dividuals [11], yet later [10], the same group reported in-
creased levels of excreted 11-dehydro-TxB2 in obese com-
pared to nonobese women associated with android obe-
sity. Interestingly, both β-thromboglobulin and the metabo-
lite11-dehydro-TxB2 correlatepositivelywithplateletcounts
[29, 30], and increased concentrations of these, found in
obese individuals, may simply reﬂecttheir, already discussed,
elevated counts. Dogru et al. and De Pergola et al. used sol-
uble P-selectin (sP-selectin) plasma levels as a marker of
platelet activation and found either similar level in over-
weight prediabetic and healthy individuals [13] or increased
sP-selectin in overweight and obese compared to normal-
weight individuals [12]. The latter ﬁnding failed to main-
tain signiﬁcant associations in a multiple regression that ac-
counted for various anthropometric, metabolic and inﬂam-
mation markers [12]. In the present study, we used a panel
of sensitive ﬂow cytometry determinants not previously re-
ported in apparently healthy obese and nonobese individu-
als. Flow cytometry is particularly well suited for discrimi-
nating between various early activation events. Flow cytom-
etry is highly sensitive in its ability to demonstrate expres-
sion of active membrane epitopes preceding early activation-
induced platelet morphological changes. This method is also
capable of detecting activated platelets in the circulation de-
spite their rapid clearance [18, 19, 31]. The present study
demonstrates no evidence of increased platelet activation
in obese subjects despite the fact that obese and morbidly
obese subjects exhibited chronic inﬂammation. Our results
are consistent with those of Dogru et al. and De Pergola et al.
[12, 13] and with the study published by Marquardt et al.
[32] that found no correlation between inﬂammation mark-
ers including leukocyte count, CRP and ﬁbrinogen levels,
and platelet membrane p-selectin (CD62p) expression in pa-
tients after an ischemic stroke.
REFERENCES
[1] R. H. Eckel and R. M. Krauss, “American Heart Association
call to action: obesity as a major risk factor for coronary heart
disease,” Circulation, vol. 97, no. 21, pp. 2099–2100, 1998.
[2] J. S. Yudkin, M. Kumari, S. E. Humphries, and V. Mohamed-
Ali, “Inﬂammation, obesity, stress and coronary heart disease:
is interleukin-6 the link?” Atherosclerosis, vol. 148, no. 2, pp.
209–214, 2000.
[3] S. Baatout, “Interleukin-6 and megakaryocytopoiesis: an up-
date,” Annals of Hematology, vol. 73, no. 4, pp. 157–162, 1996.
[4] H. Q. Ly, A. J. Kirtane, S. A. Murphy, et al., “Association of
platelet counts on presentation of clinical outcomes in ST-
elevation myocardial infarction,” American Journal of Cardi-
ology, vol. 98, no. 1, pp. 1–5, 2006.
[ 5 ]D .J .H .M c C a b e ,P .H a r r i s o n ,I .J .M a c k i e ,e ta l . ,“ I n -
creased platelet count and leucocyte-platelet complex forma-
tion in acute symptomatic compared with asymptomatic se-
vere carotid stenosis,” Journal of Neurology, Neurosurgery and
Psychiatry, vol. 76, no. 9, pp. 1249–1254, 2005.
[6] J. J. Michiels, Z. Berneman, W. Schroyens, G. Finazzi, U.
Budde, and H. H. D. M. Van Vliet, “The paradox of platelet
activationandimpairedfunction:platelet-vonWillebrandfac-
tor interactions, and the etiology of thrombotic and hem-
orrhagic manifestations in essential thrombocythemia and
polycythemia vera,” Seminars in Thrombosis and Hemostasis,
vol. 32, no. 6, pp. 589–604, 2006.
[7] C. E. Collins and D. S. Rampton, “Review article: platelets
in inﬂammatory bowel disease—pathogenetic role and ther-
apeutic implications,” Alimentary Pharmacology & Therapeu-
tics, vol. 11, no. 2, pp. 237–247, 1997.
[8] M. Nakata, T. Yada, N. Soejima, and I. Maruyama, “Leptin
promotes aggregation of human platelets via the long form of
its receptor,” Diabetes, vol. 48, no. 2, pp. 426–429, 1999.
[9] S. Konstantinides, K. Sch¨ afer, S. Koschnick, and D. J.
Loskutoﬀ, “Leptin-dependent platelet aggregation and arte-
rial thrombosis suggests a mechanism for atherothrombotic6 Mediators of Inﬂammation
disease in obesity,” Journal of Clinical Investigation, vol. 108,
no. 10, pp. 1533–1540, 2001.
[10] G. Davi, M. T. Guagnano, G. Ciabattoni, et al., “Platelet ac-
tivation in obese women: role of inﬂammation and oxidant
stress,” Journal of the American Medical Association, vol. 288,
no. 16, pp. 2008–2014, 2002.
[11] G. Licata, R. Scaglione, C. Giammarresi, and G. Davi, “No
evidence of platelet activation in obesity,” Thrombosis and
Haemostasis, vol. 70, no. 3, p. 544, 1993.
[12] G. De Pergola, N. Pannacciulli, M. Coviello, et al., “sP-selectin
plasma levels in obesity: association with insulin resistance
and related metabolic and prothrombotic factors,” Nutrition,
Metabolism and Cardiovascular Diseases. In press.
[13] T.Dogru,I.Tasci,A.Sonmez,etal.,“Theplasmalevelsofsolu-
ble P-selectin in subjects with prediabetes,” International Jour-
nal of Clinical Practice, vol. 60, no. 9, pp. 1048–1052, 2006.
[ 1 4 ]J .T .D o u g l a s ,G .D .O .L o w e ,C .D .F o r b e s ,a n dC .R .M .
Prentice, “β-thromboglobulin and platelet counts-eﬀect of
malignancy, infection, age and obesity,” Thrombosis Research,
vol. 25, no. 6, pp. 459–464, 1982.
[15] S. M. Grundy, H. B. Brewer Jr., J. I. Cleeman, S. C. Smith Jr.,
and C. Lenfant, “Deﬁnition of metabolic syndrome: Report of
theNationalHeart,Lung,andBloodInstitute/AmericanHeart
Association conference on scientiﬁc issues related to deﬁni-
tion,” Circulation, vol. 109, no. 3, pp. 433–438, 2004.
[16] A. V. Chobanian, G. L. Bakris, H. R. Black, et al., “The Sev-
enth Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure:
the JNC 7 report,” Journal of the American Medical Association,
vol. 289, no. 19, pp. 2560–2572, 2003.
[17] N. Rifai, R. P. Tracy, and P. M. Ridker, “Clinical eﬃcacy of an
automated high-sensitivity C-reactive protein assay,” Clinical
Chemistry, vol. 45, no. 12, pp. 2136–2141, 1999.
[18] A.T omer ,L.A.Hark er ,S.K asey ,andJ .R.Eckman,“Thrombo-
genesisinsicklecelldisease,”JournalofLaboratoryandClinical
Medicine, vol. 137, no. 6, pp. 398–407, 2001.
[19] A. Tomer, S. Kasey, W. E. Connor, S. Clark, L. A. Harker, and
J. R. Eckman, “Reduction of pain episodes and prothrombotic
activityin sicklecell diseasebydietary n-3fattyacids,”Throm-
bosis and Haemostasis, vol. 85, no. 6, pp. 966–974, 2001.
[20] M. S. Green, I. Peled, and T. Najenson, “Gender diﬀerences in
platelet count and its association with cigarette smoking in a
largecohortinIsrael,”JournalofClinicalEpidemiology,vol.45,
no. 1, pp. 77–84, 1992.
[21] J. S. Yudkin, C. D. A. Stehouwer, J. J. Emeis, and S. W. Cop-
pack,“C-reactiveproteininhealthysubjects:associationswith
obesity, insulin resistance, and endothelial dysfunction: a po-
tential role for cytokines originating from adipose tissue?” Ar-
teriosclerosis, Thrombosis, and Vascular Biology,v o l .1 9 ,n o .4 ,
pp. 972–978, 1999.
[22] M. Visser, L. M. Bouter, G. M. McQuillan, M. H. Wener, and
T. B. Harris, “Elevated C-reactive protein levels in overweight
and obese adults,” Journal of the American Medical Association,
vol. 282, no. 22, pp. 2131–2135, 1999.
[23] D. C. Nieman, D. A. Henson, S. L. Nehlsen-Cannarella, et
al., “Inﬂuence of obesity on immune function,” Journal of
the American Dietetic Association, vol. 99, no. 3, pp. 294–299,
1999.
[24] F. J. Nieto, M. Szklo, A. R. Folsom, R. Rock, and M. Mer-
curi, “Leukocyte count correlates in middle-aged adults: the
atherosclerosis risk in communities (ARIC) study,” American
Journal of Epidemiology, vol. 136, no. 5, pp. 525–537, 1992.
[25] L.Lazzari,R.Henschler,L.Lecchi,P.Rebulla,R.Mertelsmann,
and G. Sirchia, “Interleukin-6 and interleukin-11 act synergis-
tically with thrombopoietin and stem cell factor to modulate
ex vivo expansion of human CD41
+ and CD61+ megakary-
ocytic cells,” Haematologica, vol. 85, no. 1, pp. 25–30, 2000.
[26] J. L. Williams, G. G. Pipia, N. S. Datta, and M. W. Long,
“Thrombopoietin requires additional megakaryocyte-active
cytokinesforoptimalexvivoexpansionofmegakaryocytepre-
cursor cells,” Blood, vol. 91, no. 11, pp. 4118–4126, 1998.
[27] A. Tangorra, G. Ferretti, G. Curatola, et al., “Altered proper-
ties of platelet membrane in childhood obesity,” Biochemistry
International, vol. 17, no. 5, pp. 837–846, 1988.
[28] T. W. Meade, M. V. Vickers, S. G. Thompson, Y. Stirling,
A. P. Haines, and G. J. Miller, “Epidemiological characteris-
tics of platelet aggregability,” British Medical Journal, vol. 290,
no. 6466, pp. 428–432, 1985.
[29] F. Fabris, M. L. Randi, A. Casonato, R. Dal Bo Zanon,
P. Bonvicini, and A. Girolami, “Clinical signiﬁcance of β-
thromboglobulin in patients with high platelet count,” Acta
Haematologica, vol. 71, no. 1, pp. 32–38, 1984.
[30] A.J .CarterandS.P .Hanley ,“Theeﬀectofplateletnumberand
haematocrit on whole blood thromboxane synthesis,” Throm-
bosis and Haemostasis, vol. 53, no. 2, pp. 225–227, 1985.
[31] R.E.Scharf,A.Tomer,U.M.Marzec,P.S.Teirstein,Z.M.Rug-
geri, and L. A. Harker, “Activation of platelets in blood perfus-
ing angioplasty-damaged coronary arteries. Flow cytometric
detection,” Arteriosclerosis and Thrombosis, vol. 12, no. 12, pp.
1475–1487, 1992.
[32] L. Marquardt, A. Ruf, U. Mansmann, et al., “Course of platelet
activation markers after ischemic stroke,” Stroke, vol. 33,
no. 11, pp. 2570–2574, 2002.